Business news for the stock market
Leverkusen, Germany (pta021/14.08.2024/10:00) - Biofrontera Pharma GmbH has entered into an agreement with LEO Pharma GmbH to promote two of their established dermatological brands in Germany by Biofrontera's specialized sales team. The products in scope – Advantan® (methylprednisolone aceponat) for the treatment of endogenous eczema (atopic dermatitis, neurodermatitis), contact eczema, degenerative eczema and nummular eczema, as well as Skinoren® (azelaic acid) for the topical treatment of acne vulgaris – represent widely used treatments to support patients suffering from the underlying diseases, both by dermatologists and general practitioners.
The agreement underlines Biofrontera's commitment as a leading company in dermatology to expand its business in the European market.
Pilar de la Huerta, Managing Director of Biofrontera Pharma GmbH and CFO of Biofrontera AG, comments, "I'm pleased to see that we have been able to position ourselves as an attractive partner for a leading global pharma company such as LEO Pharma because of our expertise in the dermatological market. With our access to dermatologists that we have established over the years by the successful promotion of our key brand Ameluz® as a preferred PDT treatment for actinic keratoses, we believe to provide a well-suited platform to drive the further growth of LEO Pharma's products in Germany."
Furthermore, she mentions that "such an agreement is an excellent example of how we intend to expand our business in Europe on our pathway to a sustainably growing expert pharma player in dermatology both in terms of sales and profit."
LEO Pharma GmbH's Managing Director, Dr Marc Anton Heim, adds, "It satisfies me to see that Biofrontera will promote two of our key established dermatological products in Germany that already have helped treating so many patients suffering from atopic dermatitis or acne. Biofrontera has a high reputation in the market for bringing scientifically sound and value-adding information and services to healthcare professionals, which should form the basis to instill further growth into Advantan® and Skinoren®."
- end -
About Biofrontera
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Leverkusen-based company develops and markets innovative products for the treatment, protection and care of the skin. Its key products include Ameluz®, a prescription drug for the treatment of non-melanoma skin cancer and its precursors. Ameluz® has been marketed in the EU since 2012 and in the USA since May 2016. Biofrontera is one of a few German pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 and is listed on the Frankfurt Stock Exchange (Prime Standard). www.biofrontera.com
Forward-Looking Statements:
Certain statements in this press release are forward-looking. These statements may be identified by the use of forward-looking words such as "will," "anticipate," "believe," "forecast," "estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.
(end)
emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com
ISIN(s): DE000A4BGGM7 (share)
stock exchanges: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate